Table 2.
Effect of randomized treatment on duration hospitalization and clinical indicators (IRR>1.0 favors zinc)
| Zinc group (n = 48) | Placebo group (n = 46) | IRR for recovery (95% CI) | p-value | |
|---|---|---|---|---|
| Outcome | Median duration in h (IQR) | Median duration in h (IQR) | ||
| Hospitalization | 74.2 (67.3–117.5) | 68.5 (47.8–99.5) | 0.69 (0.45–1.06) | 0.089 |
| Fever (>37.5°C) | 30.2 (16.6–57.1) | 26.9 (12.4–41.2) | 0.78 (0.52–1.18) | 0.237 |
| Tachypnea* | 47.3 (28.7–86.9) | 32.5 (23.7–56.3) | 0.68 (0.44–1.03) | 0.071 |
| Nasal flaring | 39.1 (22.7–69.3) | 42.8 (23.9–72.4) | 1.00 (0.62–1.62) | 0.985 |
| Chest indrawing | 48.7 (24.6–74.3) | 46.5 (26.9–68.5) | 0.75 (0.49–1.14) | 0.176 |
*Respiratory rate ≥50 breaths/min for children aged 6–12 months and ≥40 breaths/min for children aged 12–36 months.